2022年血管外科学会无症状颈动脉狭窄临床实践指南推荐意见分析
本文解读2022年血管外科学会(SVS)无症状颈动脉狭窄临床实践指南。指南基于Mayo Clinic证据实践中心的系统评价与Meta分析(PICO框架)制定。SVS推荐无症状颈动脉狭窄≥70%且低手术风险的患者接受颈动脉内膜切除术(CEA)联合最佳药物治疗,而非单纯药物治疗,以长期预防卒中/死亡(GRADE 1B)。
要点
- 无症状颈动脉狭窄≥70%且预期寿命3至5年、围手术期卒中和死亡风险不超过3%的患者可考虑CEA、TCAR或TFCAS。
- 颈动脉干预方式的选择应基于各项干预措施是否存在高风险标准。
- 实施颈动脉支架的机构和术者须达到美国心脏协会指南规定的卒中和死亡合并发生率低于3%的专家水平。
核心结论
- SVS推荐无症状颈动脉狭窄≥70%且低手术风险的患者接受CEA联合最佳药物治疗,而非单纯药物治疗,以长期预防卒中/死亡(GRADE 1B)。
- 颈动脉干预应基于各项干预(CEA、TCAR和TFCAS)是否存在高风险标准。
研究设计与样本
- 指南由Mayo Clinic证据实践中心采用指定的PICO框架进行系统评价和Meta分析制定,基于已发表的随机试验和相关支持证据。
主要发现
- SVS推荐无症状颈动脉狭窄≥70%的患者可考虑CEA、TCAR或TFCAS以降低长期卒中风险,前提是预期寿命3至5年且围手术期卒中和死亡风险不超过3%。
- CREST、ACT和血管质量倡议(Vascular Quality Initiative)的数据提示,经适当选择的特定无症状患者在有经验的介入医师手中接受颈动脉支架治疗可获得与CEA等同的结局。
关键数值与推荐
- SVS推荐:无症状颈动脉狭窄≥70%且低手术风险的患者接受CEA联合最佳药物治疗,而非单纯药物治疗,以长期预防卒中/死亡(GRADE 1B)。
- 实施颈动脉支架的机构和术者须达到美国心脏协会指南标准,即卒中和死亡合并发生率低于3%。
- 颈动脉干预方式的选择应基于每项干预措施是否存在高风险标准。
临床怎么用
- 对无症状颈动脉狭窄≥70%且低手术风险的患者,推荐CEA联合最佳药物治疗以长期预防卒中/死亡(GRADE 1B)。
- 对预期寿命3至5年、围手术期卒中和死亡风险不超过3%的无症状颈动脉狭窄≥70%患者,可考虑CEA、TCAR或TFCAS。
- 颈动脉干预方式的选择应基于各项干预措施是否存在高风险标准。
- 实施颈动脉支架的机构和术者须达到美国心脏协会指南标准(卒中和死亡合并发生率低于3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with asymptomatic carotid artery stenosis currently account for the majority of carotid interventions performed in the United States; therefore, the following article will review the 2022 Society for Vascular Surgery (SVS) clinical practice guidelines perspective in treating patient with asymptomatic carotid stenosis. METHODS: A systemic review and meta-analysis were conducted by the evidence practice center of the Mayo Clinic using a specified population, intervention, comparison, outcome (PICO) framework. RESULTS: Based on published randomized trials and related supporting evidence, the following were noted: the SVS recommends that patients with asymptomatic ≥70% stenosis can be considered for carotid endarterectomy (CEA), transcarotid artery revascularization (TCAR), or transfemoral carotid artery stenting (TFCAS) for the reduction of long-term risk of stroke, provided the patient has a life expectancy of 3 to 5 years with risk of perioperative stroke and death not exceeding 3%. The type of carotid intervention should be based on the presence or absence of high-risk criteria for each specified intervention. Data from CREST, ACT, and the Vascular Quality Initiative suggest that certain properly selected asymptomatic patients can be treated with carotid stenting with equivalent outcome to CEA in the hands of experienced interventionalists. The institutions and operator performing carotid stenting must exhibit expertise sufficient to meet the established American Heart Association guidelines for treatment of patient with asymptomatic carotid stenosis (ie, combined stroke/death rate of less than 3%). CONCLUSIONS: SVS recommends that low surgical risk patients with asymptomatic carotid stenosis of ≥70% to be treated with CEA with best medical therapy over medical therapy alone for the long-term prevention of stroke/death (GRADE 1B). Carotid intervention should also be based on the presence or absence of high-risk criteria for each specified intervention (ie, CEA, TCAR, and TFCAS).
引用
- AbuRahma A. An analysis of the recommendations of the 2022 Society for Vascular Surgery clinical practice guidelines for patients with asymptomatic carotid stenosis. J Vasc Surg. 2023. PMID: 38157995. doi:10.1016/j.jvs.2023.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。